A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

@article{Glantz1999ARC,
  title={A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.},
  author={Michael J. Glantz and Kurt A. Jaeckle and Marc C Chamberlain and Surasak Phuphanich and Lawrence Recht and L. Swinnen and B. L. Maria and Susan LaFollette and G. Berry Schumann and Bernard F. Cole and Stephen B. Howell},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1999},
  volume={5 11},
  pages={3394-402}
}
Standard treatment for neoplastic meningitis requires frequent intrathecal (IT) injections of chemotherapy and is only modestly effective. DepoCyt is a sustained-release formulation of cytarabine that maintains cytotoxic concentrations of the drug in the cerebrospinal fluid (CSF) for more than 14 days after a single 50-mg injection. We conducted a randomized, controlled trial of DepoCyt versus methotrexate in patients with solid tumor neoplastic meningitis. Sixty-one patients with… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS